價(jià)格 | ¥148 | ¥197 | ¥318 |
包裝 | 1mg | 2mg | 5mg |
最小起訂量 | 1mg |
發(fā)貨地 | 上海 |
更新日期 | 2024-12-12 |
中文名稱:化合物 NXY059 | 英文名稱:Disufenton sodium |
CAS:168021-79-2 | 品牌: TargetMol |
產(chǎn)地: 美國 | 保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
純度規(guī)格: ≥98% | 產(chǎn)品類別: 抑制劑 |
貨號: T6201 |
名稱 | Disufenton sodium |
描述 | Disufenton sodium (NXY-059), a new-type nitrone, exhibits potently neuroprotective effects. |
體外活性 | NXY-059 is more soluble than the spin trapping agent α-phenyl-N-tert-butyl nitrone (PBN). [1] In an in vitro blood-brain barrier (BBB) model, 250 mM of NXY-059 administered at the onset or up to 4 h after oxygen glucose deprivation (OGD) produces a significant reduction in the increased BBB permeability caused by OGD. Furthermore, OGD produces a huge influx of tissue plasminogen activator across the BBB, which is substantially reduced by NXY-059. [2] |
體內(nèi)活性 | NXY-059 reduces infarct volume in rats subjected to 2 hours of middle cerebral artery occlusion in a dose-dependent manner. At equimolar doses (3.0 mg/kg for NXY-059 and 1.4 mg/kg for PBN), NXY-059 is more efficacious than PBN. Similar results are obtained when a recovery period of 7 days is allowed. The window of therapeutic opportunity for NXY-059 is 3 to 6 hours after the start of recirculation. [1] NXY-059, a free radical-trapping agent, has a substantial protective effect, lessening the disability caused by an experimentally induced stroke in a primate species. NXY-059 treatment reduces the overall amount of brain damage by >50% of saline-treatment values, with similar levels of protection afforded to both white and gray matter. [3] Treatment with NXY-059 (50 mg/kg subcutaneous plus 8.8 mg/kg/h for 3 days subcutaneous delivered via implanted osmotic pumps) significantly decreases neurological impairment following intracerebral hemorrhage in rat, and reduces the neutrophil infiltrate observed 48 hours post-hemorrhage in the vicinity of the hematoma, and the number of TUNEL-positive cells 48 hours post-hemorrhage at the hematoma margin. [4] |
存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | H2O : 70 mg/mL (183.6 mM) Ethanol : < 1 mg/mL (insoluble or slightly soluble) DMSO : 45 mg/mL (118.01 mM) |
關(guān)鍵字 | Disufenton sodium | Inhibitor | Reactive Oxygen Species | OKN-007 | OKN 007 | inhibit | Disufenton |
相關(guān)產(chǎn)品 | Lycopene | Coenzyme Q10 | Sodium 2-oxopropanoate | Sodium Thiocyanate | Glucosamine | D-(+)-Glucono-1,5-lactone | Ammonium sulfate | Imeglimin hydrochloride | L-Ascorbic acid | Acetylcysteine | Naringenin | Dimethyl fumarate |
相關(guān)庫 | 神經(jīng)保護(hù)化合物庫 | 抗乳腺癌化合物庫 | 經(jīng)典已知活性庫 | 抗癌活性化合物庫 | 已知活性化合物庫 | 抗衰老化合物庫 | 藥物功能重定位化合物庫 | 銅死亡化合物庫 | 抗癌臨床化合物庫 | 抗癌藥物庫 |
成立日期 | 2013-04-18 (12年) | 注冊資本 | 566.265100萬人民幣 |
員工人數(shù) | 100-500人 | 年?duì)I業(yè)額 | ¥ 1億以上 |
主營行業(yè) | 天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù) | 經(jīng)營模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢價(jià) |
VIP1年
|
青島愷潤生物醫(yī)藥科技有限公司
|
2025-02-07 | |
詢價(jià) |
VIP5年
|
山東沃德森生物科技有限公司
|
2025-02-12 | |
詢價(jià) |
VIP3年
|
陜西締都新材料有限公司
|
2024-12-18 | |
¥442.90 |
VIP13年
|
上海阿拉丁生化科技股份有限公司
|
2025-01-20 | |
¥600 |
南京百鑫德諾生物科技有限公司
|
2024-09-26 |